Profil bibliographique

SH Lee

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

346Publications signalées

3726Citations signalées

6Affiliations récentes

Les institutions déclarées

Samsung Medical Center CHA University Bundang Medical Center Jeju National University Hospital Dong-A University Jeju National University Sungkyunkwan University

Les domaines associés

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCardiac Arrest and ResuscitationColorectal Cancer Treatments and StudiesLung Cancer Research Studies

Les publications récentes

2025 article OpenAlex

A Qualitative Case Study on the Career Choice of Multicultural Adolescents Outside of School

Eui-joong Kim, SH Lee

본 연구는 학교 밖 다문화 청소년의 진로선택 과정을 탐색하고, 이들의 진로준비를 지원하기 위한 제도적·사회적 방안을 모색하는 데 목적이 있다. 이를 위해 학교 밖 다 문화 청소년 4명을 연구 참여자로 선정하여 집단 심층면접과 개별면접을 실시하였다. 수집된 자료를 바탕으로 사례 내 분석과 사례 간 …

0 citations The Jounal of Cultural Exchange

2025 article OpenAlex

P1.11.32 Quality of Life Outcomes from the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy (ATTLAS, KCSG-LU19-04) in EGFR/ALK- Mutated NSCLC

Eun Joo Kang, Sehhoon Park, Taek Min Kim, J-Y. Han et autres

kr, us, Éthiopie, pr, jp (code pays fourni par la source)

0 citations Journal of Thoracic Oncology

2025 article OpenAlex

PT1.03.06 Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA

Hidetoshi Hayashi, Benjamin Besse, SH Lee, Lu Shen et autres

jp, fr, kr, cn, us, gb, tw, il, br, ar, tr, es, ca (code pays fourni par la source)

5 citations Journal of Thoracic Oncology

2025 article OpenAlex

P3.18.09 SUNRAY-02: A Phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC After Definitive Therapy

Ernest Nadal, Jamie E. Chaft, M. Garassino, Jhanelle E. Gray et autres

es, us, kr, fr, gb, nl, jp, cn, de (code pays fourni par la source)

3 citations Journal of Thoracic Oncology

2025 article OpenAlex

P2.08.31 Clinical and Imaging Characteristics Associated With Pathologic Response After Neoadjuvant Chemoimmunotherapy in Stage II-III NSCLC

Dong Young Jeong, Jae Kwan Lee, Hye Yeon Lee, Hyung‐Kwan Kim et autres

kr (code pays fourni par la source)

0 citations Journal of Thoracic Oncology

Accès ouvert 2025 article OpenAlex

1946P MYTX-011, a pH-dependent cMET-targeting ADC, demonstrates anti-tumor activity across a broad spectrum of cMET expressing NSCLC

Elaine Shum, Valentina Gambardella, SH Lee, A. Greystoke et autres

us, es, kr, gb, fr, au, tw (code pays fourni par la source)

0 citations Annals of Oncology

Accès ouvert 2025 article OpenAlex

1948P Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial

Aaron S. Mansfield, S. Lu, J.W. Goldman, SH Lee et autres

us, cn, kr, il, ca, nl (code pays fourni par la source)

0 citations Annals of Oncology

Accès ouvert 2025 article OpenAlex

1950P Ocular surface disorders in patients with c-Met protein–overexpressing NSCLC treated with telisotuzumab vedotin in the LUMINOSITY study

Nathalie Daaboul, J.W. Goldman, H. Horinouchi, SH Lee et autres

ca, us, kr, il (code pays fourni par la source)

1 citation Annals of Oncology

Accès ouvert 2025 article OpenAlex

1490P Infiltrative HCC defines a clinically and molecularly distinct subtype with poor clinical outcomes from atezolizumab plus bevacizumab

Hong Jae Chon, Won Suk Lee, Sun‐Hee Woo, SH Lee et autres

kr (code pays fourni par la source)

0 citations Annals of Oncology

Accès ouvert 2025 article OpenAlex

1348MO SKYSCRAPER-09: Phase II, randomised study of tiragolumab (tira) + atezolizumab (atezo) and atezo + placebo (pbo) as first-line (1L) treatment in patients (pts) with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck (R/M SCCHN)

Amanda Psyrri, Christophe Le Tourneau, A. Daste, Arunee Dechaphunkul et autres

gr, fr, th, tw, us, kr, gb, ch (code pays fourni par la source)

2 citations Annals of Oncology

Accès ouvert 2025 article OpenAlex

1324MO ASPEN-04: A randomized phase II study of evorpacept in combination with pembrolizumab and chemotherapy in patients with recurrent, unresectable or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

K.J. Harrington, Ming Hong, Beatriz Cirauqui, J-P. Machiels et autres

gb, kr, es, be, nl, au, us (code pays fourni par la source)

1 citation Annals of Oncology

Accès ouvert 2025 article OpenAlex

2973P Prognostic significance of POU2F3 expression in thymic epithelial tumors

Y-J. Bang, Gunhyuk Park, T. Kim, Ji Hoon Kim et autres

kr (code pays fourni par la source)

0 citations Annals of Oncology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.